ARK Genomic (Switzerland) Performance

ARKG Etf   4.28  0.05  1.15%   
The etf shows a Beta (market volatility) of 1.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ARK Genomic will likely underperform.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days ARK Genomic has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, ARK Genomic is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
1
Cathie Wood Doubles Down On Bitcoin ETF Amid Crypto Chaos, Drops 3.9M On This Amazon Rival - inkl
12/01/2025
2
cathie woods ARK stock trades highlight ionis pharma sale By Investing.com - Investing.com Nigeria
12/19/2025
3
Cathie Woods ARK ETF Buys Intellia, Personalised Stock Sells Illumina By Investing.com - Investing.com India
01/09/2026
4
Cathie Wood Ark Invest bets bigger on Bullish amid 16 percent surge - Cryptopolitan
02/10/2026
  

ARK Genomic Relative Risk vs. Return Landscape

If you would invest  453.00  in ARK Genomic on December 3, 2025 and sell it today you would lose (25.00) from holding ARK Genomic or give up 5.52% of portfolio value over 90 days. ARK Genomic is generating negative expected returns and assumes 2.4869% volatility on return distribution over the 90 days horizon. Simply put, 22% of etfs are less volatile than ARK, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days trading horizon ARK Genomic is expected to under-perform the market. In addition to that, the company is 3.29 times more volatile than its market benchmark. It trades about -0.03 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.05 per unit of volatility.

ARK Genomic Target Price Odds to finish over Current Price

The tendency of ARK Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 4.28 90 days 4.28 
about 80.92
Based on a normal probability distribution, the odds of ARK Genomic to move above the current price in 90 days from now is about 80.92 (This ARK Genomic probability density function shows the probability of ARK Etf to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon the etf has the beta coefficient of 1.18 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ARK Genomic will likely underperform. Additionally ARK Genomic has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   ARK Genomic Price Density   
       Price  

Predictive Modules for ARK Genomic

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ARK Genomic. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
1.794.286.77
Details
Intrinsic
Valuation
LowRealHigh
1.864.356.84
Details
Naive
Forecast
LowNextHigh
2.144.637.11
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
4.284.284.28
Details

ARK Genomic Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. ARK Genomic is not an exception. The market had few large corrections towards the ARK Genomic's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ARK Genomic, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ARK Genomic within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.05
β
Beta against Dow Jones1.18
σ
Overall volatility
0.24
Ir
Information ratio -0.01

ARK Genomic Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ARK Genomic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ARK Genomic can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
ARK Genomic generated a negative expected return over the last 90 days
Latest headline from news.google.com: Cathie Wood Ark Invest bets bigger on Bullish amid 16 percent surge - Cryptopolitan

About ARK Genomic Performance

Evaluating ARK Genomic's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if ARK Genomic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ARK Genomic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
ARK Genomic is entity of Switzerland. It is traded as Etf on SW exchange.
ARK Genomic generated a negative expected return over the last 90 days
Latest headline from news.google.com: Cathie Wood Ark Invest bets bigger on Bullish amid 16 percent surge - Cryptopolitan

Other Information on Investing in ARK Etf

ARK Genomic financial ratios help investors to determine whether ARK Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ARK with respect to the benefits of owning ARK Genomic security.